Ensign Peak Advisors Inc raised its stake in Humana Inc (NYSE:HUM) by 90.0% in the 1st quarter, HoldingsChannel reports. The firm owned 221,305 shares of the insurance provider’s stock after acquiring an additional 104,836 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Humana were worth $69,495,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Norges Bank acquired a new position in Humana during the 4th quarter worth approximately $477,049,000. Jennison Associates LLC increased its holdings in shares of Humana by 507.7% during the first quarter. Jennison Associates LLC now owns 1,256,095 shares of the insurance provider’s stock valued at $394,439,000 after acquiring an additional 1,049,394 shares in the last quarter. Capital Research Global Investors raised its position in shares of Humana by 15.2% during the fourth quarter. Capital Research Global Investors now owns 7,829,472 shares of the insurance provider’s stock worth $2,869,658,000 after purchasing an additional 1,033,910 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Humana by 257.4% in the 4th quarter. AQR Capital Management LLC now owns 1,168,090 shares of the insurance provider’s stock worth $428,129,000 after purchasing an additional 841,298 shares in the last quarter. Finally, Man Group plc lifted its holdings in shares of Humana by 254.9% in the 4th quarter. Man Group plc now owns 506,272 shares of the insurance provider’s stock worth $185,559,000 after purchasing an additional 363,626 shares in the last quarter. Hedge funds and other institutional investors own 93.18% of the company’s stock.
Several research analysts have weighed in on the stock. Cantor Fitzgerald upped their price objective on shares of Humana from $345.00 to $400.00 and gave the stock an “overweight” rating in a report on Wednesday, February 5th. Zacks Investment Research cut shares of Humana from a “buy” rating to a “hold” rating and set a $396.00 price target on the stock. in a research report on Friday, April 17th. Morgan Stanley boosted their price objective on Humana from $375.00 to $500.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. CSFB raised their target price on Humana from $400.00 to $423.00 and gave the company an “outperform” rating in a report on Thursday, April 30th. Finally, Barclays reaffirmed a “buy” rating on shares of Humana in a research report on Sunday, March 29th. Seven investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $405.42.
Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $5.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.84 by $0.56. Humana had a net margin of 3.86% and a return on equity of 21.02%. The company had revenue of $18.94 billion during the quarter, compared to analyst estimates of $18.49 billion. During the same quarter last year, the business posted $4.48 EPS. Humana’s quarterly revenue was up 17.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Humana Inc will post 18.55 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.625 per share. The ex-dividend date of this dividend is Monday, June 29th. This represents a $2.50 dividend on an annualized basis and a dividend yield of 0.62%. Humana’s dividend payout ratio is presently 13.99%.
In related news, Director David A. Jr/Ky Jones sold 5,800 shares of Humana stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $256.19, for a total value of $1,485,902.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.42% of the stock is currently owned by corporate insiders.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
See Also: Why do companies engage in swaps?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.